2025-09-15 - Analysis Report
Okay, here's a report analyzing Natera (NTRA) based on the data you provided.

## Natera (NTRA) Stock Analysis

**Ticker:** NTRA
**Company:** Natera Inc.
**Description:** Natera Inc. is a diagnostics company focusing on cell-free DNA testing.

### 1. Performance vs. S&P 500 (VOO)

*   **NTRA Cumulative Return:** 159.76%
*   **VOO Cumulative Return:** 104.78%
*   **Spread:**
    *   Current: 65.9%
    *   Max: 630.1%
    *   Min: -29.0%
    *   Relative Spread: 14.4%

**Analysis:** NTRA has significantly outperformed the S&P 500 (VOO) in cumulative return.  However, the "Relative Spread" of 14.4% indicates that its current outperformance is closer to the lower end of its historical range relative to the S&P 500. This suggests that the current spread, while positive, isn't as extreme as it has been in the past.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta | Cap(B) |
|------------|---------|--------|---------|------|--------|
| 2015-2017  | -6.0%   | 62.4%  | -31.0%  | 0.0  | 1.2    |
| 2016-2018  | 29.0%   | 80.1%  | 11.0%   | 0.0  | 1.9    |
| 2017-2019  | 159.0%  | 80.1%  | 130.0%  | 1.2  | 4.6    |
| 2018-2020  | 530.0%  | 80.1%  | 510.0%  | 0.3  | 13.7   |
| 2019-2021  | 355.0%  | 62.9%  | 307.0%  | 0.2  | 12.8   |
| 2020-2022  | -119.0% | 62.9%  | -121.0% | 0.2  | 5.5    |
| 2021-2023  | -482.0% | 69.9%  | -500.0% | 1.1  | 8.6    |
| 2022-2024  | -75.0%  | 70.6%  | -100.0% | 1.2  | 21.7   |
| 2023-2025  | 109.0%  | 76.1%  | 52.0%   | 0.8  | 23.1   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows wide swings in performance.  The period 2018-2020 saw exceptional growth, while 2021-2023 experienced a significant decline.  Recent performance (2023-2025) is positive.
*   **MDD:** Maximum Drawdown (MDD) is consistently high, indicating significant volatility.
*   **Alpha:**  Alpha fluctuates, reflecting periods of significant outperformance (positive Alpha) and underperformance (negative Alpha) compared to the market.
*   **Beta:** Beta is generally low (around 0), suggesting the stock has not been strongly correlated with the overall market but the BETA value has increased to around 1 recently.

### 2. Recent Stock Price Movement

*   **Current Price:** 168.51
*   **Previous Close:** 173.81
*   **Change:** -3.05
*   **5-Day Moving Average:** 171.17
*   **20-Day Moving Average:** 166.35
*   **60-Day Moving Average:** 157.15

**Analysis:** The stock price has recently decreased, indicated by the negative change. The 5-day moving average is above the 20-day and 60-day moving averages, but has been decreasing, which can be a short-term bearish signal. The 20-day moving average is above the 60-day moving average, which can be a bullish signal. The recent negative price change (-3.05 from previous close of 173.81 to current price of 168.51) signals a notable downward fluctuation.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 53.25
*   **PPO:** -0.0346
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) (Cash Ratio: 0% on 2025-09-03)
*   **20-Day Relative Spread Change:** -0.3 (Short-term Decline)
*   **Expected Return:** 151.8%

**Analysis:**

*   **MRI:** The Market Risk Indicator suggests a low-risk environment, but the Hybrid Signal reflects a cautious approach, recommending buying a portion of available cash.
*   **RSI:** The RSI is at 53.25, indicating a neutral market, neither overbought nor oversold.
*   **PPO:** The PPO is negative, suggesting a slight downward trend in momentum.
*   **20-Day Relative Spread Change:** The negative change suggests a recent short-term decline relative to the S&P 500.
*   **Expected Return:** The high expected return (151.8%) suggests significant potential for long-term outperformance compared to the S&P 500, assuming a buy-and-hold strategy.

### 4. Recent News & Significant Events

*   **Negative News:** Several articles highlight reasons for recent stock price declines.  (e.g., "Why Natera (NTRA) Stock Is Trading Lower Today," "Why Natera (NTRA) Shares Are Falling Today")
*   **Positive News:** Some articles express optimism about Natera (e.g., "3 Reasons Weâ€™re Fans of Natera (NTRA)").
*   **Trial Data:** The ARCHER trial and its potential impact on valuation are being discussed.
*   **Market Trends:** Natera is mentioned in the context of the liquid biopsy market, indicating its involvement in a growing sector.

**Analysis:** The news sentiment is mixed. While there are articles pointing to potential reasons for current price drops, there are also articles highlighting positive aspects of the company and its future prospects. The ARCHER trial results seem to be a significant factor influencing investor sentiment.

### 4-2. Analyst Opinions

*   **Consensus:** Strong Buy (Mean: 1.45)
*   **Number of Opinions:** 20
*   **Target Price:**
    *   Average: 198.45
    *   High: 268.00
    *   Low: 37.00
*   **Recent Rating Changes:** No changes indicated in the provided data.

**Analysis:**  The analyst consensus is strongly positive, with a "Strong Buy" rating and a significant number of opinions. The average target price is substantially higher than the current price, indicating potential upside.  The wide range between the high and low target prices (37.00 and 268.00) suggests significant uncertainty among analysts regarding the stock's future performance.

### 5. Recent Earnings Analysis

| Date       | EPS   | Revenue    |
|------------|-------|------------|
| 2025-08-08 | -0.74 | 0.55 B$    |
| 2025-05-09 | -0.50 | 0.50 B$    |
| 2024-11-12 | -0.26 | 0.44 B$    |
| 2024-08-09 | -0.30 | 0.41 B$    |
| 2025-08-08 | -0.30 | 0.41 B$    |

**Analysis:**

*   **EPS:** The company has consistently reported negative Earnings Per Share (EPS), indicating a lack of profitability.
*   **Revenue:** Revenue has generally been increasing over the past few quarters, which is a positive sign. However, the recent (2025-08-08) value is bigger than the old (2025-08-08) value
*   **Trend:** While revenue is growing, the continued negative EPS raises concerns about the company's ability to achieve profitability.

### 6. Financial Information

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.55B    | 63.41%        |
| 2025-03-31 | $0.50B    | 63.12%        |
| 2024-12-31 | $0.48B    | 62.94%        |
| 2024-09-30 | $0.44B    | 61.79%        |
| 2024-06-30 | $0.41B    | 58.83%        |

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-06-30 | $1.25B    | -8.10%   |
| 2025-03-31 | $1.24B    | -5.40%   |
| 2024-12-31 | $1.20B    | -4.50%   |
| 2024-09-30 | $0.88B    | -3.60%   |
| 2024-06-30 | $0.84B    | -4.48%   |

**Analysis:**

*   **Revenue:** Revenue is showing a consistent upward trend.
*   **Profit Margin:** The profit margin is consistently high (above 58%), suggesting good cost control and pricing power.
*   **Equity:** Equity has been increasing.
*   **ROE:** Return on Equity (ROE) is negative, reflecting the company's lack of profitability.  While improving, it remains a key area of concern.

### 7. Overall Summary

**Key Observations:**

*   **Performance:** NTRA has outperformed the S&P 500 historically, but recent performance has been mixed.
*   **Volatility:** The stock is highly volatile, as indicated by the high MDD values.
*   **Analyst Sentiment:** Analyst consensus is strongly positive, with high target prices.
*   **Financials:** Revenue is growing, and profit margins are high, but the company is not yet profitable, as evidenced by negative EPS and ROE.
*   **News:** Recent news sentiment is mixed, with some articles highlighting concerns about price drops and others emphasizing positive aspects.
*   **Risk:** The MRI suggests low market risk, but the Hybrid Signal indicates a need for caution.

**Conclusion:**

Natera (NTRA) presents a mixed picture.  The company operates in a growth sector (liquid biopsy market), has strong revenue growth and high profit margins. Analyst's consensus is strongly positive. However, it is not yet profitable and exhibits high volatility. Recent news suggests potential headwinds, but also ongoing positive developments.

**Recommendation:**

Given the mixed signals, a cautious approach is warranted. While the long-term expected return is high, the short-term risks are also significant. Investors should carefully consider their risk tolerance and conduct further due diligence before investing in NTRA. Monitor upcoming news and trial data closely.
